Address And Details

One Financial Center , Boston, MA 02111
Fund Manager Joseph R. Gatz
Manager Tenure 21 Years 8 Months

Strategy And Objective

The Fund s investment objective is long-term capital growth from investments in common stocks or other equity securities. The Fund normally will invest at least 80% of its net assets (plus any borrowings made for investment purposes) in the equity securities of small-cap companies, including preferred stocks, warrants, securities convertible into common or preferred stocks and other equity-like interests in an entity. Currently, the Fund defines a small-cap company to be one whose market capitalization falls within the capitalization range of the Russell 2000 Index, an index that tracks stocks of 2,000 of the smallest U.S. companies. The Fund may invest the rest of its assets in companies of any size, including large-capitalization companies. In deciding which securities to buy and sell, Loomis Sayles seeks to identify securities of smaller companies that it believes are undervalued by the market. Loomis Sayles will consider, among other things, price-to-earnings, price-to-book and price-to-cash flow ratios. The Fund s investments may include companies that have suffered significant business problems but are believed by Loomis Sayles to have favorable prospects for recovery and companies that are not yet well-known to the investment community but are considered to have favorable fundamental prospects and attractive valuation. The portfolio managers analyze fundamental trends across the various industries in the sectors and use this information along with security valuation procedures to determine which stocks they believe are best positioned to outperform the industry or sector. Sell decisions are made when there is a deterioration in fundamentals, a stock reaches a target price or a more attractive opportunity is found. The Fund may invest up to 20% of its assets in foreign securities, including emerging markets securities. Although certain equity securities purchased by the Fund may be issued by domestic companies incorporated outside of the United States, the Adviser does not consider these securities to be foreign if they are included in the U.S. equity indices published by S&P Global Ratings or Russell Investments. The Fund may also invest in real estate investment trusts( REITs ), securities issued pursuant to Rule 144A under the Securities Act of 1933 ( Rule 144A securities ) and, to the extent permitted by the Investment Company Act of 1940, and the rules thereunder (the 1940 Act ), investment companies. The Fund may engage, for hedging and investment purposes, in foreign currency transactions (such as forward currency contracts), options and futures transactions.

Net Asset Value

as of 5:24 PM ET 09/24/2021

Performance

  • 1 Week
  • +1.71%
  • 1 Month
  • +0.51%
  • 3 Months
  • -1.16%
  • 1 Yr Return
  • +48.91%
  • 5 Yr Return
  • -5.47%

Equity Sector Breakdown

Finance 21.87%
IndustrialCyclical 17.75%
Technology 12.85%
Services 7.24%
Health 6.05%
NonDurables 5.80%
RetailTrade 5.71%
ConsumerDurables 5.15%
Utilities 3.25%
Energy 0.82%

Asset Allocation

Asset Type % Of Allocation
Stocks 98.82%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
Other 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 106.03 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -11.83 -9.43 -6.20
Beta 1.24 1.21 1.19
R Squared 0.83 0.77 0.78
Std Deviation 25.19 20.71 18.04
Sharpe Ratio 0.37 0.53 n/a

Purchase Information

as of 5:23 PM ET 09/23/2021
Minimum Initial $2500
Minimum Additional $50
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +48.24%
  • +58.68%
+48.24% +58.68%
3 Year
  • +6.96%
  • +8.68%
+6.96% +8.68%
10 Year
  • +11.52%
  • +10.15%
+11.52% +10.15%
Life Of Fund
  • +9.68%
  • +9.74%
+9.68% +9.74%

Top 10 Holdings

Symbol Company Name % Of Assets
TBK TRIUMPH BANCORP INC 1.56%
HRI HERC HOLDINGS INC 1.51%
ACA ARCOSA INC 1.39%
CHX CHAMPIONX CORPORATION 1.38%
BPOP POPULAR INC 1.36%
KAI KADANT 1.36%
CNXC CONCENTRIX CORPORATION 1.33%
WTFC WINTRUST FINANCIAL CORP 1.29%
PNFP PINNACLE FINANCIAL PARTNERS 1.23%
CASH META FINANCIAL GROUP INC 1.22%

LATEST NEWS

Recent Articles from TheStreet

China Power Firms Suspend Publication Of Coal Data, Frustrating Analysis Of Industrial Production

Jim Cramer's Read on Industrial Production

Latest data remains encouraging for economy.

United Airlines

United Airlines Faces Department of Transportation Fine

United Airlines faces a $1.9 million fine from the Department of Transportation for violating federal statutes and a DOT rule prohibiting long tarmac delays.

NYSE Trader Lead

Jim Cramer IDs an Underappreciated Investing Rule

It's not enough to just identify stocks you want to own.

Home Construction, and Regional and Community Bank ETFs Reflect a Healthy Housing Market

Jim Cramer Says Latest Housing Data is Mixed for Millenials

There are signs more rental units are being built, but single family dwellings are still tight.

Closing Bell: Rite Aid Spikes on FTC Negotiations; U.S. Stocks Fall

Rite Aid Teams With Uber Eats for Nationwide On-Demand Delivery

Rite Aid expands its on-demand delivery options, adding a partnership with Uber Technologies to deliver products nationwide through Uber Eats.

Amazon Prime Lead

Whole Foods Adds Service Fee for Amazon Prime Deliveries

Amazon's Whole Foods Market is ending free deliveries for Amazon Prime members, as it will add a $9.95 service fee beginning in October.

FedEx Lead

FedEx Is a Sell, Guilfoyle Says

Delivery giant recently missed estimates and has been late to raise prices.

intel (4)

Intel Starts Construction of Two Arizona Computer Chip Factories

Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.

A technician works with genome samples at a biotech lab in Beijing. Photo: Reuters

Bret Jensen: Two Biotechs to Consider

Things are looking up for these drug companies as they make progress with the FDA